Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 110
Filtrar
1.
ESMO Open ; 7(4): 100551, 2022 08.
Artigo em Inglês | MEDLINE | ID: mdl-35930972

RESUMO

BACKGROUND: Data for selpercatinib [a selective REarranged during Transfection (RET) inhibitor] from a single-arm trial (LIBRETTO-001, NCT03157128) in RET-fusion-positive advanced/metastatic non-small-cell lung cancer (NSCLC) were used in combination with external data sources to estimate comparative efficacy [objective response rate (ORR), progression-free survival, and overall survival (OS)] in first- and second-line treatment settings. METHODS: Patient-level data were obtained from a de-identified real-world database. Patients diagnosed with advanced/metastatic NSCLC with no prior exposure to a RET inhibitor and one or more prior line of therapy were eligible. Additionally, individual patient-level data (IPD) were obtained from the pemetrexed + platinum arm of KEYNOTE-189 (NCT03950674, first line) and the docetaxel arm of REVEL (NCT01168973, post-progression). Patients were matched using entropy balancing, doubly robust method, and propensity score approaches. For patients with unknown/negative RET status, adjustment was made using a model fitted to IPD from a real-world database. RESULTS: In first-line unadjusted analyses of the real-world control, ORR was 87.2% for LIBRETTO-001 versus 66.7% for those with RET-positive NSCLC (P = 0.06). After adjustment for unknown RET status and other patient characteristics, selpercatinib remained significantly superior versus the real-world control for all outcomes (all P < 0.001 except unadjusted RET-fusion-positive cohort). Similarly, outcomes were significantly improved versus clinical trial controls (all P < 0.05). CONCLUSIONS: Findings suggest improvement in outcomes associated with selpercatinib treatment versus the multiple external control cohorts, but should be interpreted with caution. Data were limited by the rarity of RET, lack of mature OS data, and uncertainty from assumptions to create control arms from external data.


Assuntos
Carcinoma Pulmonar de Células não Pequenas , Neoplasias Pulmonares , Humanos , Inibidores de Proteínas Quinases , Proteínas Proto-Oncogênicas c-ret , Pirazóis , Piridinas
2.
Physiol Res ; 70(2): 265-272, 2021 04 30.
Artigo em Inglês | MEDLINE | ID: mdl-33676384

RESUMO

It has been suggested that sympathetic activity, measured as changes in electrical skin impedance (SI), can be used to assess the adequacy of general anesthesia. Our prospective study investigated if measurements of skin impedance can determine levels of sedation induced by midazolam. Twenty-seven patients scheduled for arthroscopy requiring general anesthesia were served as their own control. These were blinded to the order of injections by telling them that they will be randomly administered a placebo (saline) orsedative agent. A DM 3900 multimeter was used for SI measurements. The degree of sedation was measured using the modified Observer's Assessment of Alertness and Sedation (mOAAS) scale. Resting SI values were noted, and all participants were then administered the placebo followed 5 min later by midazolam 2 mg i.v. Five min after that, patients were administered standard general anesthesia with propofol, oxygen, nitrous oxide 60 %, and isoflurane 1 MAC via a laryngeal mask, and sufentanil 5 - 10 µg. SI significantly increased after administration of midazolam and induction of anesthesia. There were no significant differences between pre-administration (baseline) and placebo and end of surgery and end of anesthesia with closed eyes. There were highly significant differences (p<0.001) between pre-administration vs. midazolam, placebo vs. midazolam, pre-administration vs. induction of anesthesia. We found slight correlation between mOAAS and SI. There were no significant changes between the end of surgery and the end of anesthesia with closed eyes, but SI significantly decreased (p<0.01) after eyes opened.


Assuntos
Período de Recuperação da Anestesia , Estado de Consciência/efeitos dos fármacos , Resposta Galvânica da Pele/efeitos dos fármacos , Hipnóticos e Sedativos/uso terapêutico , Midazolam/uso terapêutico , Pele/inervação , Sistema Nervoso Simpático/efeitos dos fármacos , Adulto , Anestesia Geral , República Tcheca , Método Duplo-Cego , Impedância Elétrica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Sistema Nervoso Simpático/fisiologia , Fatores de Tempo
3.
Physiol Res ; 68(Suppl 1): S97-S103, 2019 11 22.
Artigo em Inglês | MEDLINE | ID: mdl-31755295

RESUMO

Remifentanil is ultrashort-acting opioid with a unique pharmacokinetic profile. It is used exclusively intravenously. While considering its rapid onset of action and other pharmacokinetic properties, we decided to assess its effects following administration via non-traditional routes. Rabbits (n=10 per each group) were randomized into six groups: remifentanil 1 microg/kg and 3 microg/kg IM, 5.0 and 10.0 microg/kg conjunctivally, and 10 microg/kg and 25.0 microg/kg intranasally. Sedating effects were assessed via a loss of the righting reflex. Secondary, mean arterial blood pressure, arterial oxygen saturation of hemoglobin, and pulse rate was monitored in all rabbits. Non-traditional routes of administration were shown to provide a rapid onset of action as well as fast recovery. Importantly, the administration of remifentanil did not result in any deterioration of cardiovascular functions.


Assuntos
Analgésicos Opioides/administração & dosagem , Remifentanil/administração & dosagem , Dor Aguda/tratamento farmacológico , Administração Intranasal , Administração Oftálmica , Animais , Pressão Sanguínea/efeitos dos fármacos , Túnica Conjuntiva/efeitos dos fármacos , Relação Dose-Resposta a Droga , Feminino , Frequência Cardíaca , Hemoglobinas/metabolismo , Hipnóticos e Sedativos , Injeções Intramusculares , Masculino , Oxigênio/sangue , Coelhos , Reflexo de Endireitamento/efeitos dos fármacos , Remifentanil/farmacocinética
4.
Arch Pediatr ; 26(1): 12-15, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30558858

RESUMO

BACKGROUND: The incidence of meningitis caused by Klebsiella pneumoniae (Kp) and Klebsiella oxytoca (Ko) in high-income countries is unknown, and no series have been published to date. METHODS: We conducted a nationwide multicenter observational study in France between 2006 and 2016. All children from the French national registry for paediatric bacterial meningitis under the age of 1 year and hospitalized for Kp or Ko meningitis were included. Virulence factors of four Klebsiella spp. strains were explored by whole genome sequencing. RESULTS: Of 1859 cases of meningitis in children under the age of 1 year, 13 cases (0.7%) of Klebsiella spp. meningitis (nine for Kp meningitis and four for Ko meningitis) were registered in the French national registry. Three of the patients died and 50% of the survivors had developmental delays. CONCLUSIONS: Prematurity, low birth weight, and congenital anomalies of the urinary tract appear to be risk factors for Klebsiella spp. meningitis as well as virulence factors of the strain.


Assuntos
Infecções por Klebsiella/epidemiologia , Klebsiella oxytoca/genética , Klebsiella pneumoniae/genética , Meningites Bacterianas/epidemiologia , Antibacterianos/uso terapêutico , Feminino , França/epidemiologia , Humanos , Incidência , Lactente , Recém-Nascido , Infecções por Klebsiella/tratamento farmacológico , Imageamento por Ressonância Magnética , Masculino , Meningites Bacterianas/tratamento farmacológico , Meningites Bacterianas/microbiologia , Sistema de Registros , Fatores de Risco , Taxa de Sobrevida , Fatores de Virulência/genética , Sequenciamento Completo do Genoma
5.
Physiol Res ; 65(Suppl 4): S473-S480, 2016 12 21.
Artigo em Inglês | MEDLINE | ID: mdl-28006929

RESUMO

Oxytocin is a hormone therapeutically used mainly for its peripheral effects during pregnancy in the uterus and breasts. However, additional central effects, i.e. anxiolytic effect, decreased level of social stress and increased empathy have been also observed. Hence, the aim of our study was to evaluate if nasal oxytocin can be used as anxiolytic substance in rhesus monkeys (n=20) and rabbits (n=20). Simultaneously, mean arterial blood pressure, arterial oxygen saturation of hemoglobin and pulse rate were monitored in all the evaluated animals. While rabbits lost righting reflex, monkeys developed a dose-dependent loss of aggressiveness and/or anxiety as evaluated by behavioral methods (aggressive behavior was classified as non-sedated - sedated - strongly sedated).


Assuntos
Agressão/efeitos dos fármacos , Ansiolíticos/administração & dosagem , Hipnóticos e Sedativos/administração & dosagem , Ocitocina/administração & dosagem , Administração Intranasal , Agressão/fisiologia , Animais , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Feminino , Frequência Cardíaca/efeitos dos fármacos , Frequência Cardíaca/fisiologia , Macaca mulatta , Masculino , Coelhos , Distribuição Aleatória
6.
Respir Physiol Neurobiol ; 185(2): 304-12, 2013 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-23041446

RESUMO

Both obesity and sleep reduce lung volume and limit deep breaths, possibly contributing to asthma. We hypothesize that increasing lung volume dynamically during sleep would reduce airway resistance in asthma. Asthma (n=10) and control (n=10) subjects were studied during sleep at baseline and with increased lung volume via bi-level positive airway pressure (BPAP). Using forced oscillations, respiratory system resistance (R(rs)) and reactance (X(rs)) were measured during sleep and R(rs) was partitioned to upper and lower airway resistance (R(up), R(low)) using an epiglottic pressure catheter. R(rs) and R(up) increased with sleep (p<0.01) and X(rs) was decreased in REM (p=0.02) as compared to wake. R(rs), R(up), and R(low), were larger (p<0.01) and X(rs) was decreased (p<0.02) in asthma. On BPAP, R(rs) and R(up) were decreased (p<0.001) and X(rs) increased (p<0.01), but R(low) was unchanged. High R(up) was observed in asthma, which reduced with BPAP. We conclude that the upper airway is a major component of R(rs) and larger lung volume changes may be required to alter R(low).


Assuntos
Resistência das Vias Respiratórias/fisiologia , Asma/etiologia , Obesidade/complicações , Sobrepeso/complicações , Respiração com Pressão Positiva , Sono/fisiologia , Adolescente , Adulto , Idoso , Análise de Variância , Índice de Massa Corporal , Feminino , Humanos , Complacência Pulmonar , Medidas de Volume Pulmonar , Masculino , Cloreto de Metacolina/farmacologia , Pessoa de Meia-Idade , Agonistas Muscarínicos/farmacologia , Vigília/fisiologia , Adulto Jovem
7.
J Med Primatol ; 41(4): 251-5, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22594699

RESUMO

BACKGROUND: Ephedrine is used in treatment of hypotension during anesthesia. We investigated its effects on the psychomotor recovery and its potential adverse reactions on cardiorespiratory functions in rhesus monkeys. METHODS: The monkeys received 50 µg/kg medetomidine, 2.0 mg/kg S-ketamine with 150 IU hyaluronidase i.m. Pulse rate, blood pressure and saturation of haemoglobin were monitored for 20 minutes. Thereafter, 1 mg/kg of ephedrine or a placebo was administered i.m. and behavioural changes, pulse rate, blood pressure and saturation of haemoglobin were monitored every 5 minutes. RESULTS: Ephedrine shortened recovery from anaesthesia from 80.4 ± 25.8 to 14.83 ± 13.70 minutes. Ephedrine also increased oxygen saturation of haemoglobin and systolic blood pressure and caused significant decrease in pulse rate 5 minutes after its administration. CONCLUSIONS: Ephedrine can be successfully used to accelerate psychomotor recovery after the use of common anesthetic protocols combining dissociative anesthetic agent and alpha 2-adrenoceptor agonist in primates.


Assuntos
Adrenérgicos/farmacologia , Período de Recuperação da Anestesia , Pressão Sanguínea/efeitos dos fármacos , Efedrina/farmacologia , Desempenho Psicomotor/efeitos dos fármacos , Anestésicos Dissociativos , Animais , Feminino , Hipnóticos e Sedativos , Ketamina , Macaca mulatta , Masculino , Medetomidina , Pulso Arterial
8.
Physiol Res ; 61(1): 63-72, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22188112

RESUMO

Inhalational anesthetics have demonstrated cardioprotective effects against myocardial ischemia-reperfusion injury. Clinical studies in cardiac surgery have supported these findings, although not with the consistency demonstrated in experimental studies. Recent investigations have questioned the advantages of inhalational over intravenous anesthetics with respect to cardiac protection. Ketamine has been shown to be comparable with sufentanil, and has even demonstrated anti-inflammatory properties. Dexmedetomidine has been established as a sedative/anesthetic drug with analgesic properties, and has also demonstrated myocardial protective effects. In this retrospective observational study, the influence of ketamine-dexmedetomidine-based anesthesia (KET-DEX group; n=17) on the release of cardiac biomarkers was compared with that of sevoflurane-sufentanil-based anesthesia (SEVO group; n=21) in patients undergoing elective coronary artery bypass grafting. Compared with the SEVO group, the KET-DEX group exhibited significantly reduced cardiac troponin I (2.22+/-1.73 vs. 3.63+/-2.37 microg/l; P=0.02) and myocardial fraction of creatine kinase (CK-MB) levels (12.4+/-10.4 vs. 20.3+/-11.2 microg/l; P=0.01) on the morning of the first postoperative day. Furthermore, cardiac troponin I release, evaluated as the area under the curve, was significantly reduced in the KET-DEX group (32.1+/-20.1 vs. 50.6+/-23.2; P=0.01). These results demonstrate the cardioprotective effects of ketamine-dexmedetomidine anesthesia compared with those of sevoflurane-sufentanil anesthesia.


Assuntos
Anestésicos Combinados , Anestésicos Inalatórios , Cardiotônicos/farmacologia , Idoso , Biomarcadores/sangue , Dexmedetomidina , Feminino , Humanos , Ketamina , Masculino , Éteres Metílicos , Pessoa de Meia-Idade , Estudos Retrospectivos , Sevoflurano , Sufentanil , Cirurgia Torácica
9.
Rozhl Chir ; 89(5): 275-81, 2010 May.
Artigo em Tcheco | MEDLINE | ID: mdl-20666328

RESUMO

THE AIM OF THE STUDY: Recently, alpha2 sympathoadrenergic drugs are used in premedication to improve the perioperative course. The aim of our study was to compare a premedication with a new alpha2 sympathoadrenergic drug and standard premedication. METHODS: After ethic committee approval and written patient consent, in a randomised, double-blinded study, combination of dexmedetomidine 1.0 microg x kg(-1) + ketamine 0.5 mg x kg(-1) + fentanyl 1.0 microg x kg(-1) + atropine 0.5 mg (group FNT), dexmedetomidine 1.0 microg x kg(-1) + ketamine 0.5 mg x kg(-1) + alfentanil 5.0 microg x kg(-1) + atropine 0.5 mg (group ALFNT), or pethidine 1.0 mg x kg(-1) + atropine 0.5 mg (group Dolsin) was administered to a deltoid muscle 15 min. before anaesthesia (GA) in patients elicited for laparoscopic cholecystectomy (LCHE). GA was performed in a standard way, ECG, NIBP, respiration rate, SpO2, onset of effect, Observers Assessment of Alertness Sedation Score (OAASS) before GA, circulatory reaction to intubation and capnoperitoneum, fentanyl consumption during GA, time to the first request for post-operative analgesia and postoperative nausea and vomiting were measured. The data were processed by Kruskal-Wallis and Fisher tests. P-value < 0.05 was considered significant. RESULTS: There were 16 patients in FNT and Dolsin and 15 patients in ALFNT with no differences in demography except for younger age in ALFNT. The main differences were in hypertension during capnoperitoneum: 0/16 FNT and 1/15 ALFNT vs. 11/16 Dolsin, both p < 0.001, per-operative fentanyl consumption: FNT 31.5 microg vs. Dolsin 165.0 microg, p < 0.001 and ALFNT 50.0 microg, p < 0.05 (ALFNT vs. Dolsin, p < 0.01) and request to the first analgesic post surgery: FNT 1.3 h. vs. Dolsin 0.45 h., p < 0.05 vs. ALFNT 0.8 h., p < 0.01. There were no differences in side effects except for bradycardia in ALFNT (p < 0.05). CONCLUSIONS: Dexmedetomidine-ketamine-fentanyl-atropine combination is superior to pethidine-atropine combination in suppressing of adverse hemodynamic effects of capnoperitoneum, decreased need for analgesia during GA and prolonged postoperative analgesia.


Assuntos
Anestésicos Combinados/administração & dosagem , Colecistectomia Laparoscópica , Hemodinâmica/efeitos dos fármacos , Dor Pós-Operatória/prevenção & controle , Analgésicos não Narcóticos , Analgésicos Opioides/administração & dosagem , Período de Recuperação da Anestesia , Anestésicos Dissociativos/administração & dosagem , Atropina/administração & dosagem , Dexmedetomidina/administração & dosagem , Método Duplo-Cego , Feminino , Fentanila/administração & dosagem , Humanos , Hipnóticos e Sedativos/administração & dosagem , Ketamina/administração & dosagem , Masculino , Meperidina/administração & dosagem , Pessoa de Meia-Idade
10.
J Trauma ; 69(1): 211-4, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20622592

RESUMO

Trauma during pregnancy has presented very unique challenges over the centuries. From the first report of Ambrose Pare of a gunshot wound to the uterus in the 1600s to the present, there have existed controversies and inconsistencies in diagnosis, management, prognostics, and outcome. Anxiety is heightened by the addition of another, smaller patient. Trauma affects 7% of all pregnancies and requires admission in 4 of 1000 pregnancies. The incidence increases with advancing gestational age. Just over half of trauma during pregnancy occurs in the third trimester. Motor vehicle crashes comprise 50% of these traumas, and falls and assaults account for 22% each. These data were considered to be underestimates because many injured pregnant patients are not seen at trauma centers. Trauma during pregnancy is the leading cause of nonobstetric death and has an overall 6% to 7% maternal mortality. Fetal mortality has been quoted as high as 61% in major trauma and 80% if maternal shock is present. The anatomy and physiology of pregnancy make diagnosis and treatment difficult.


Assuntos
Complicações na Gravidez/diagnóstico , Ferimentos e Lesões/diagnóstico , Cesárea , Feminino , Idade Gestacional , Humanos , Gravidez , Complicações na Gravidez/terapia , Ferimentos e Lesões/complicações , Ferimentos e Lesões/terapia
11.
Physiol Res ; 59(5): 703-710, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20406031

RESUMO

Hemorrhagic shock (HS) represents an acute event with high mortality. The optimal combination of anesthetics that would prevent hemodynamic collapse and allow damage control surgery has not yet been determined. We tested the hypothesis that a combination of dissociative anesthetic ketamine with alpha2-agonist medetomidine (MK group, n=10) would provide superior hemodynamic control compared to propofol-remifentanil (PR group, n=10) during HS in minipigs. A modified Wiggers' model of HS with a target mean arterial pressure (MAP) of 40 mm Hg and 2 h duration was used. All minipigs survived. HS led to a ~50 % decrease in cardiac output in both groups (P<0.001 for baseline vs. HS 120 min) with no differences between groups. Total volume of removed blood was larger in the MK group (1321+/-133 ml vs. 1111+/-246 ml in the PR group, respectively; P<0.05). MAP was higher during the initial phases of HS in the MK group than in PR group (P<0.05 at HS 30-90 min). HR was lower in the MK group at the late phases of HS (P<0.05 at HS 60-120 min). In conclusion, medetomidine-ketamine provides a feasible and possibly a more favorable alternative to the propofol-remifentanil combination in our model of HS in minipigs.


Assuntos
Anestésicos Dissociativos/farmacologia , Hemodinâmica/efeitos dos fármacos , Hipnóticos e Sedativos/farmacologia , Ketamina/farmacologia , Medetomidina/farmacologia , Choque Hemorrágico/fisiopatologia , Anestesia/métodos , Animais , Pressão Sanguínea/efeitos dos fármacos , Volume Sanguíneo , Débito Cardíaco/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Piperidinas/farmacologia , Propofol/farmacologia , Remifentanil
12.
J Med Primatol ; 39(3): 151-9, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20202075

RESUMO

BACKGROUND: The aim of the study was to compare the effect of naphthylmedetomidine to medetomidine on the behavior of orangutans and chimpanzees. METHODS: The immobilization was performed as part of a medical examination in five chimpanzees and three orangutans. Following pre-medication with midazolam (0.70-1.20 mg/kg p.o.), naphthylmedetomidine (50-70 microg/kg), or medetomidine (20-30 microg/kg) was given with ketamine (3 mg/kg) and hyaluronidase (150 M.U.) into musculus deltoideus. RESULTS: We observed the distinct anti-aggressive effect of naphthylmedetomidine. The immobilization with naphthylmedetomidine was shallower and the influence on cardiac frequency less substantial compared to medetomidine. The overall sedative effect of naphthylmedetomidine lasted for less time, and its effect was incompletely antagonized with atipamezole in comparison to medetomidine. CONCLUSIONS: Naphthylmedetomidine could replace medetomidine for inducing immobilization and sedation. A combination of naphthylmedetomidine-ketamine is suitable for relocating animals to other cages or for painless medical examinations.


Assuntos
Hialuronoglucosaminidase/administração & dosagem , Imobilização/veterinária , Ketamina/administração & dosagem , Medetomidina/análogos & derivados , Pan troglodytes , Pongo , Animais , Feminino , Imobilização/métodos , Masculino , Medetomidina/administração & dosagem
13.
J Intellect Disabil Res ; 53(1): 11-8, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18771512

RESUMO

BACKGROUND: Previous studies suggested that children diagnosed with fragile X syndrome (FXS) often meet criteria for autism or PDD. This study describes the fine motor abilities of children diagnosed with FXS with and without autism spectrum disorder, and compares the motor scores of those groups controlling for cognitive level. METHOD: Forty-eight children, ages 12-76 months (SD = 16) diagnosed with FXS were assessed with the Mullen Scales of Early Learning, and the Autism Diagnostic Observation Schedule. Their parents were interviewed with the Autism Diagnostic Interview-Revised. We used a one-way analysis of variance to determine if the fine motor scale of the Mullen would show group differences based on autism classifications for the sample. In addition, we used Pearson correlation coefficient to examine the relationship between the cognitive level, the autism severity and the motor abilities. Lastly, we conducted a one-way analysis of covariance to determine the difference between the motor abilities of the Autism Spectrum Disorder groups controlling for cognitive level. RESULTS: We found that 60% of the children with FXS met criteria for autism or Pervasive Developmental Disorder - Not otherwise specified (PDD-NOS). Children with FXS with autism and PDD-NOS had lower fine motor scores than those without. However, there was no significant association between degree of motor impairment and communication and social impairments after controlling for cognitive level, indicating that cognitive level contributes to impaired motor abilities of children diagnosed with FXS and autism, more than the severity of autism symptoms. CONCLUSION: children with FXS and autism are at risk for impaired motor abilities. Implications for development and intervention are discussed.


Assuntos
Transtorno Autístico/epidemiologia , Transtornos Globais do Desenvolvimento Infantil/epidemiologia , Síndrome do Cromossomo X Frágil/epidemiologia , Transtornos das Habilidades Motoras/epidemiologia , Análise de Variância , Transtorno Autístico/psicologia , California/epidemiologia , Criança , Comportamento Infantil/psicologia , Transtornos Globais do Desenvolvimento Infantil/psicologia , Pré-Escolar , Cognição , Comorbidade , Feminino , Síndrome do Cromossomo X Frágil/psicologia , Humanos , Lactente , Desenvolvimento da Linguagem , Masculino , Destreza Motora , Transtornos das Habilidades Motoras/diagnóstico , Transtornos das Habilidades Motoras/psicologia , Pais , Fatores de Risco , Índice de Gravidade de Doença , Comportamento Social , Percepção Visual
14.
Gynecol Oncol ; 107(2): 260-5, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17675142

RESUMO

OBJECTIVE: Platinum/Paclitaxel-based chemotherapy is a current treatment for advanced epithelial ovarian cancer. We sought to explore the association between weight change during treatment and survival, as well as the association between pre-chemotherapy body mass index (BMI) and survival. METHODS: A retrospective data review was conducted of 792 advanced ovarian cancer patients who participated in a phase III randomized trial of cisplatin/paclitaxel versus carboplatin/paclitaxel. Pre-chemotherapy BMI was calculated following surgery. Weight change was defined as the ratio of body weight at completion of protocol therapy to pre-chemotherapy body weight. Progression-free survival (PFS) and overall survival (OS), classified by BMI or relative weight change, were estimated by Kaplan-Meier, and associations were assessed using a Cox model controlled for known prognostic variables (age, race, performance status, histology, tumor grade, tumor residual and treatment group). RESULTS: There was no association between pre-chemotherapy BMI and survival. There was a significant relationship between median OS and weight change as follows: >5% decrease=48.0 months; 0-5% decrease=49.3 months; 0-5% increase=61.1 months; and >5% increase=68.2 months. Adjusted for covariates, the relative risk of death increased by 7% for each 5% decrease in body weight (HR=0.93, 95% CI=0.88-0.99; p=0.013). CONCLUSIONS: Change of body weight during primary chemotherapy was a strong prognostic factor for overall survival. Loss of body weight during primary therapy is an indicator for poor OS; weight gain is an indicator for improved survival. This study supports the development of strategies to minimize weight loss that can be assessed in a prospective, randomized study to improve patient outcomes.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/mortalidade , Aumento de Peso , Redução de Peso , Adulto , Idoso , Índice de Massa Corporal , Peso Corporal , Carboplatina/administração & dosagem , Carcinoma/tratamento farmacológico , Carcinoma/mortalidade , Cisplatino/administração & dosagem , Ensaios Clínicos Fase III como Assunto , Cistadenocarcinoma Seroso/tratamento farmacológico , Cistadenocarcinoma Seroso/mortalidade , Feminino , Humanos , Estimativa de Kaplan-Meier , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasias Ovarianas/patologia , Neoplasias Ovarianas/cirurgia , Paclitaxel/administração & dosagem , Valor Preditivo dos Testes , Prognóstico , Ensaios Clínicos Controlados Aleatórios como Assunto , Estudos Retrospectivos , Estados Unidos/epidemiologia
15.
Int J Gynecol Cancer ; 17(3): 561-70, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17504373

RESUMO

Ovarian cancer is the fourth leading cause of cancer death among women in the United States. First-line chemotherapy offered to patients with ovarian cancer generally consists of an intravenous (IV) platinum plus taxane regimen and has remained virtually unchanged for the past 10 years. A number of recently completed phase III randomized trials in the United States have reported improved progression-free survival (PFS) and/or overall survival (OS) with the intraperitoneal (IP) administration of cisplatin. The purpose of this study was to pool the published data to perform a meta-analysis of randomized trials of IP cisplatin in the initial chemotherapy treatment of ovarian cancer patients. This study was initiated to obtain a more valid estimate of the therapeutic impact of IP treatment for these patients. A search strategy was initiated that searched published findings of randomized trials of IP cisplatin therapy from multiple sources from January 1990 through January 2006. Six randomized trials of 1716 ovarian cancer patients were identified and included in this analysis. The pooled hazard ratio (HR) for PFS of IP cisplatin as compared to IV treatment regimens is 0.792 (95% CI: 0.688-0.912, P= 0.001), and the pooled HR for OS is 0.799 (95% CI: 0.702-0.910, P= 0.0007). These findings strongly support the incorporation of an IP cisplatin regimen to improve survival in the front-line treatment of stage III, optimally debulked ovarian cancer.


Assuntos
Carcinoma/tratamento farmacológico , Cisplatino/administração & dosagem , Terapia Neoadjuvante , Neoplasias Ovarianas/tratamento farmacológico , Algoritmos , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Carcinoma/mortalidade , Cisplatino/efeitos adversos , Feminino , Humanos , Infusões Parenterais , Pessoa de Meia-Idade , Neoplasias Ovarianas/mortalidade , Ensaios Clínicos Controlados Aleatórios como Assunto , Projetos de Pesquisa , Análise de Sobrevida , Resultado do Tratamento , Estados Unidos
16.
Gynecol Oncol ; 103(3): 783-92, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17070570

RESUMO

Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S. The concept of intraperitoneal drug delivery for therapy of intraperitoneal cancers, such as ovarian cancer, arose in the 1960s. The field of intraperitoneal cisplatin therapy for ovarian cancer was initiated in the late 1970s and early 1980s. The markedly improved survival data resulting from a phase III trial of intraperitoneal cisplatin for ovarian cancer in early 2006 led to an NCI Clinical Announcement and a Gynecologic Oncology Group-sponsored workshop on intraperitoneal therapy in January, 2006, in San Diego, California. The proceedings of this workshop summarize both research trial results and practical implementation issues associated with intraperitoneal therapy discussed at this workshop.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Cisplatino/administração & dosagem , Neoplasias Ovarianas/tratamento farmacológico , Paclitaxel/administração & dosagem , Congressos como Assunto , Intervalo Livre de Doença , Feminino , Humanos , Injeções Intraperitoneais , Neoplasias Ovarianas/mortalidade , Neoplasias Ovarianas/enfermagem , Ensaios Clínicos Controlados Aleatórios como Assunto , Análise de Sobrevida , Estados Unidos
17.
J Reprod Med ; 51(6): 471-4, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16846085

RESUMO

OBJECTIVE: To investigate the relationship between ERAS-based preinterview scores, residency program postinterview scores and candidate rank order for the match. STUDY DESIGN: Two hundred sixty-three candidates' preinterview and postinterview scores and rank order were evaluated. The rank order was stratified as 1-4, 5-8, 9-12, > 13 and unranked. Spearman's p statistical analysis was used. RESULTS: There was a moderate relationship, r2 = 0.543, between preinterview and postinterview scores for all applicants. There was a significant inverse correlation between preinterview score and rank order, r2 = -0.763, and for the postinterview and rank order, r2 = -0.768. However, there were no significant relationships between factors significant for the top 4 ranked candidates. CONCLUSION: Preinterview and postinterview scores significantly correlated with each other and with the rank order list except for top-ranked candidates. Other factors may influence the rank order list.


Assuntos
Ginecologia/educação , Internato e Residência/normas , Entrevistas como Assunto , Obstetrícia/educação , Processamento Eletrônico de Dados , Humanos , Pennsylvania , Critérios de Admissão Escolar
18.
J Reprod Med ; 51(3): 190-2, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16674014

RESUMO

OBJECTIVE: To compare the use of episiotomy by private practitioners vs. resident staff and to determine if number of years in practice influences episiotomy use. STUDY DESIGN: A retrospective chart review of vaginal deliveries at 35 weeks or greater between January 2001 and June 2001. The number of years in practice by each private physician was documented. Independent sample t tests and chi2 tests were used to analyze data. RESULTS: In 995 deliveries, episiotomies were performed in 6% of low-risk resident deliveries vs. 26% of low-risk private deliveries (p<0.001). Physicians in practice > or = 15 years performed episiotomies in 32% of low-risk births. Physicians in practice <15 years performed episiotomies in 22% of low-risk births (p = 0.027). CONCLUSION: Deliveries performed by private practitioners are associated with a higher rate of episiotomy than those by resident staff. The number of episiotomies appears to increase by number of years in practice.


Assuntos
Episiotomia/estatística & dados numéricos , Internato e Residência/estatística & dados numéricos , Padrões de Prática Médica/estatística & dados numéricos , Prática Privada/estatística & dados numéricos , Adolescente , Adulto , Criança , Feminino , Humanos , Pessoa de Meia-Idade , Estudos Retrospectivos
19.
Praxis (Bern 1994) ; 95(5): 139-46, 2006 Feb 01.
Artigo em Alemão | MEDLINE | ID: mdl-16509450

RESUMO

AIM: To asses the prevalence of potentially critical drug-drug interactions (DDIs) in outpatients treated with a statin. PATIENTS/METHODS: Data of patients (e.g. age, sex, comorbidities, individual statin, number of drugs, number of diagnoses) were collected from 242 Swiss practitioners. The medication was screened electronically for potentially critical DDIs. RESULTS: We included 2742 statin-treated patients (mean age 65.1 +/- 11.2 [SD] years, 3.2 +/- 1.6 diagnoses, 4.9 +/- 2.4 drugs prescribed) from the German (53.3%), French (36%) or Italian speaking (10.7%) part of Switzerland. Of those, 401 (14.6%) had a total of 591 potentially severe DDIs; 190 patients (6.9%) had potential statin DDIs, 288 (10.5%) potential non-statin DDIs, mainly due to pharmacodynamic mechanisms. The prevalence of potential DDIs was similar between regions, except for a trend for a higher prevalence of drug-statin interactions in the French-speaking part. The number of drugs per patient and a diagnosis of arrhythmia or heart failure were identified as risk factors for DDIs. CONCLUSIONS: Drug combinations with potentially severe DDIs are common in patients treated with statins due to pharmacotherapy of their co-morbidities. Special attention in this specific population should be drawn on patients with polypharmacy and those with drug treatments for arrhythmia or heart failure.


Assuntos
Assistência Ambulatorial , Interações Medicamentosas , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Sistemas de Notificação de Reações Adversas a Medicamentos , Idoso , Comorbidade , Bases de Dados Factuais , Quimioterapia Combinada , Europa (Continente) , Feminino , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Masculino , Pessoa de Meia-Idade
20.
Talanta ; 70(4): 818-22, 2006 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-18970845

RESUMO

Sensors based on changes of refractive index in response to sorption of an analyte on the coating or film of a long period grating fiber (LPG) fiber have recently been reported. In most prior work the coating or film swelled during interaction with the analyte. The swelling mechanism produced a kinetic response that slowed both the sensor's time for steady-state measurement and the reversibility of the sensor. Here, the analytical utility of fabricating these nanometer thin films using the layer-by-layer (LBL) electrostatic assembly method is evaluated using Cu(II) as the test analyte and Cibacron Blue as the reagent immobilized in the LBL assembly; a generation-4 poly(amidoamine) dendrimer served as the spacer in the assembly. Detection of 1.3mgCu(II)L(-1) was observed when six bilayers comprised the coating. The stable response was achieved with 0.6mgL(-1) in less than 1min. When 0.1M HCl was used as the rinsing solution, this LPG sensor was reversible and the signal to similar concentrations of Cu(II) reproducible.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA